Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Oncology Reports
Published in: Current Oncology Reports 8/2021

01-08-2021 | Correction

Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review

Authors: Caleb J. Smith, Yahya Almodallal, Aminah Jatoi

Published in: Current Oncology Reports | Issue 8/2021

Login to get access

Excerpt

Correction to: Current Oncology Reports …
Metadata
Title
Correction to: Rare Adverse Events with Programmed Death-1 and Programmed Death-Ligand 1 Inhibitors: Justification and Rationale for a Systematic Review
Authors
Caleb J. Smith
Yahya Almodallal
Aminah Jatoi
Publication date
01-08-2021
Publisher
Springer US
Published in
Current Oncology Reports / Issue 8/2021
Print ISSN: 1523-3790
Electronic ISSN: 1534-6269
DOI
https://doi.org/10.1007/s11912-021-01101-2

Other articles of this Issue 8/2021

Current Oncology Reports 8/2021 Go to the issue

Cardio-oncology (EH Yang, Section Editor)

The Role and Impact of Social Media in Cardio-oncology During the COVID-19 Pandemic

Genitourinary Cancers (DP Petrylak and JW Kim, Section Editors)

Prostate Cancer Immunotherapy—Finally in From the Cold?

Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Frontline Maintenance Treatment for Ovarian Cancer

Palliative Medicine (A Jatoi, Section Editor)

Navigating the Cancer Screening Decision for Patients with Dementia

Gynecologic Cancers (J Brown and RW Naumann, Section Editors)

Progress in Gynecologic Cancers with Antibody Drug Conjugates

Evolving Therapies (RM Bukowski, Section Editor)

ROS1 Targeted Therapies: Current Status
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits